Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Purchased by Portland Global Advisors LLC

Portland Global Advisors LLC raised its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 3.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 268,988 shares of the company’s stock after acquiring an additional 9,373 shares during the period. Portland Global Advisors LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $2,612,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in GNOM. Rockefeller Capital Management L.P. acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at about $205,000. SBI Securities Co. Ltd. acquired a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $50,000. Sanctuary Advisors LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at about $104,000. Atria Investments Inc grew its position in shares of Global X Genomics & Biotechnology ETF by 27.8% during the fourth quarter. Atria Investments Inc now owns 13,813 shares of the company’s stock worth $134,000 after buying an additional 3,006 shares in the last quarter. Finally, Oxinas Partners Wealth Management LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter worth approximately $103,000. 56.95% of the stock is currently owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Down 1.9 %

Shares of Global X Genomics & Biotechnology ETF stock opened at $8.35 on Friday. Global X Genomics & Biotechnology ETF has a 52-week low of $8.31 and a 52-week high of $11.88. The company has a market capitalization of $58.20 million, a P/E ratio of -3.57 and a beta of 1.03. The company has a 50 day moving average of $9.44 and a 200 day moving average of $10.14.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.